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Retinal pigment epithelial detachment (PED) is a common manifestation in several retinal conditions including age-related macular degeneration 1 . Based on retinal imaging as well as clinical examination, PEDs can be classified as drusenoid, serous or vascular 2, 3, 4 . Vascularised PEDs, as the name suggest, are associated with choroidal neovascularization (CNV). Drusenoid and serous PEDs may or may not have an associated CNV. Anti-VEGF therapy has a well proven role in the treatment of vascularized PED 5, 6 . Less well established is the beneficial effect of anti-VEGF therapy in those PEDs where a CNV is not clearly present. Large serous PEDs were excluded from phase 3 clinical trials such as TAP, ANCHOR and MARINA 7, 8, 9 trials. As such these trials cannot be relied upon to provide management strategies for these lesions.
Development of a rip in a PED can result in permanent damage to central vision 10, 11 . Such a rip is Pak J Ophthalmol often spontaneous although intravitreal therapy can also precipitate an RPE rip 12, 13 . It is therefore desirable to reduce the height of a PED in order to minimize the risk of a rip. Furthermore, a longstanding PED presumably interferes with the nutrition to the RPE and photoreceptors and thus early flattening of the PED or reducing its height was an important treatment rationale in this study. No universally agreed guidelines exist on the treatment of PEDs not associated with a CNV. One study 14 looked specifically at the role of the anti-VEGF agent, Ranibizumab (Lucentis) in non-vascularised PEDs but the follow-up period in that study was 12 months. The purpose of this study was to look at the long term effects of 3 Ranibizumab injections given in eyes with non-vascularised PEDs. The effects were monitored for up to 36 months and to date this is the longest follow-up published for this sub-set of treated patients.
METHODS
In this study, we looked at eyes with fovea involving avascular PED of at least 100 microns height, which were treated with 3 injections of intravitreal Ranibizumab between 2011 and 2013. All patients had a baseline visual acuity of at least 50 ETDRS letters. Absence of associated choroidal neovascularization (CNV) was established by structural OCT and fluorescein angiography (Heidelberg Spectralis). Patients with co-existing macular pathology such as diabetic macular edema, CSCR, retinal angiomatous proliferation (RAP) and epiretinal membrane were not treated with anti-VEGF.
At pre-treatment baseline, all patients had demographic characteristics recorded such as date of birth, sex, race and a general health questionnaire. Best corrected visual acuity was recorded using ETDRS letter score. Volume OCT scanning of the macula was performed. Fluorescein angiography was performed in all patients to rule out presence of CNV. OCT Angiography was not available at the time. The patients were then evaluated by a retina specialist to consider suitability for Ranibizumab treatment. PED height was measured using the inbuilt calipers in the OCT software (see Fig) . Maximum vertical distance between Bruchs membrane and the RPE was used as a measure of baseline PED height. The PED was classified as drusenoid or serous based on the reflectivity of the sub-RPE space on OCT examination. Informed consent was obtained for the full course of treatment. All patients received three Ranibizumab injections at four weekly intervals according to departmental protocol. No supplementary injections were performed in these patients as we did not consider the Royal College of Ophthalmologists wet AMD guidelines to be applicable to these cases. The aim of treatment was to reduce height of the PED in order to prevent the possibility of a future rip as well as to stabilize and improve visual acuity.
The primary outcome measures were effect on reduction in PED height and effect on visual acuity over the course of 3 years following the initial loading dose of 3 Ranibizumab injections. Following 3 initial injections all patients were monitored for up to 36 months. At each visit visual acuity was measured using ETDRS letters. PED height was measured on structural OCT scan.
RESULTS
Twelve eyes of 12 patients met the inclusion criteria for this study. There were 7 females and 5 males. Median age was 77 (age range 58-90). At baseline, 9 PEDs were considered serous based on hyporeflectivity on OCT scanning. 3 PEDs were considered drusenoid. Mean baseline visual acuity was 59.66 ETDRS letters (range 50-69). Mean PED height was 281 microns (range 90-410). PED height reduced by 64.78 microns at month 3 following the third Ranibizumab injection. From there onwards, the reduction in height was gradual and a further mean reduction of 96.56 microns was noted between month 3 and month 36 post-injection. Least reduction in height was noted in the drusenoid PEDs although these eyes showed the most stable VA. Five eyes with serous PED showed complete resolution of the PED with no recurrence during the follow-up period. Two eyes with serous PED showed a recurrent increase in PED height to baseline levels between months 12 and 24. BCVA showed a gradual mean decrease of 6.54 ETDRS letters over the 36 months of follow-up. No eye showed development of CNV throughout the study period.
DISCUSSION
The pathogenesis of pigment epithelial detachment (PED) is not completely understood. Anatomical apposition of the RPE to the underlying Bruch's membrane is crucial for the nutritional support of the outer retina. The forces maintaining this adhesion are not fully clear. A decrease in overall conductivity across Bruch's membrane resulting in reduced fluid exchange between the choroid and RPE is considered to be a widely accepted underlying mechanism of PED formation 15 , although it may be likely that drusenoid and serous PEDs could have different pathogenesis 16 . Inflammatory mediators 17 as well as VEGF 18 have been implicated in the increased permeability across Bruch's membrane.
For ease of description, we would like to introduce the terms "dry PED" to denote avascular PEDs, as distinguished from "wet PED" which are clearly associated with choroidal neovascularization as shown by structural OCT and Fluorescein/Indocyanine Green angiography. Dry PEDs include drusenoid PEDs and serous PEDs which show no features of CNV. There is no universally accepted treatment strategy for dry PEDs. This study represents the longest published follow-up (3 years) of eyes with avascular PED treated with Ranibizumab in a real world setting. In 12 eyes of 12 patients, 3 intravitreal injections of Ranibizumab were performed to treat Dry age-related PED. Maximum reduction in PED height was seen in the first 6 months followed by a more gradual mean reduction. This effect was sustained in 10 eyes over 3 years whereas 2 eyes showed recurrence of the PED. In 5 eyes complete flattening of the PED was observed. Beneficial effect on visual acuity was less encouraging as compared to treating fibrovascular PEDs with Ranibizumab 19, 20 . However, 8 eyes maintained their baseline visual acuity. Interestingly these included the 2 eyes which developed recurrent PED. Four eyes showed a gradual decline in visual acuity over 36 months. All of these were eyes in which the PED had completely flattened and outer retinal degenerative changes gradually developed.
Our study findings compare favorably with a similar study from Vienna 14 although Ritter et al's follow-up period was 12 months compared to our 36 month follow-up. They also recruited 12 patients but half of these were treated with up to 6 Ranibizumab injections over 6 months. They also concluded that Ranibizumab treatment can reduce PED height and volume but the effect was not maintained over the 12 months period of their study. Other studies have found limited benefit of anti-VEGF in bringing about complete resolution of the PED element of wet AMD 21 whereas one large series 22 has correlated the anatomic response of treatment to baseline PED height, associated vascularization and also the type of anti-VEGF used.
The findings of this retrospective case series
Pak J Ophthalmol suggest structural benefit and visual stability in some patients with age-related "dry" PEDs treated with intravitreal Ranibizumab. This further suggests that VEGF may indeed have a role in the pathogenesis of age-related pigment epithelial detachments even when no structural or angiographic features of choroidal neovascularization are present.
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